Compare Citius Pharmaceuticals Inc (CTXR) vs Tapestry, Inc. (TPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Tapestry, Inc. — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $18.73M), while Tapestry, Inc. trades at $161 (market cap $33.29B). The key difference: Tapestry, Inc. is far larger — about 1777.4× Citius Pharmaceuticals Inc's market cap, and Tapestry, Inc. pays a 0.97% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | TPR | |
|---|---|---|
Market Cap | $18.73M | $33.29B |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $164.78 |
52-Week Low | $0.48 | $95.69 |
Enterprise Value | $14.95M | $36.15B |
Dividend Yield | — | 0.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.
The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.
TPR trades at $162.36, up 0.22% today, and is near its 52-week high with strong bullish technical signals. The company has consistently beaten earnings expectations, with Q1 2026 EPS of $1.66 exceeding the $1.30 estimate. Recent news highlights AI integration and brand momentum, while analyst consensus is strongly bullish with a $190.33 price target.
Outlook remains positive driven by earnings growth and strategic initiatives, but risks include high valuation multiples and volatile cash flows. The stock offers upside to analyst targets but faces margin pressure and competitive challenges in the retail sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Tapestry, Inc.
Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →
